Skip to content
TrialMatch
Sign up
Recruiting

Using 4D Urinary Proteomics to Predict and Evaluate Treatment Response in Colorectal Cancer

Create a profile to match View the full record on ClinicalTrials.gov

About this study

The goal of this observational study is to learn how well urinary proteins can predict treatment response in patients with locally advanced colorectal cancer (LACC) undergoing neoadjuvant therapy. The main question it aims to answer is: Can urinary protein markers help predict and evaluate how patients with LACC respond to neoadjuvant therapy? Participants diagnosed with LACC will provide urine samples before and after neoadjuvant therapy. These samples will be analyzed using 4D deep urinary proteomics and machine learning to identify proteins linked to treatment response. Some participants' tumor tissues will also be used to create organoid models for further testing.

Condition
Colorectal Cancer (CRC), Neoadjuvant Therapy, Proteomics
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Who can join

Age
18 to 75 years
Sex
All sexes
Healthy volunteers
Not accepted

Inclusion 11

  • Minimum age: 18 years
  • Maximum age: 75 years
  • Study condition: Colorectal Cancer (CRC), Neoadjuvant Therapy, Proteomics
  • Aged 18-75 years;
  • Pathologically confirmed diagnosis of locally advanced colorectal cancer (cT3-4 and/or N+);
  • Planned to undergo neoadjuvant therapy followed by surgical resection;
  • No evidence of distant metastasis (M0) confirmed by imaging (CT and/or PET-CT);
  • Clinically assessed as being able to tolerate and complete the full course of neoadjuvant treatment;
  • No prior anti-tumor therapy (e.g., targeted therapy, immunotherapy) before the initiation of treatment;
  • Willing and able to provide urine samples as required;
  • Written informed consent obtained.

Exclusion 5

  • History of or concurrent diagnosis with other malignancies;
  • Presence of severe hepatic, renal, cardiovascular, or metabolic diseases that may affect urinary protein metabolism;
  • Recent use of medications known to affect protein metabolism (e.g., glucocorticoids, high-dose antibiotics);
  • Urinary tract infection or other diseases known to cause abnormal urinary protein levels (e.g., nephrotic syndrome);
  • Any other condition deemed unsuitable for enrollment by the investigators.

Where

1 site, 1 recruiting

Cancer Hospital Chinese Academy of Medical Sciences

Beijing, Chaoyang District, China

Recruiting

Contact

Potential match only. Final eligibility is determined by the study team.